Company
Tris Pharma INC
Last checked: Nov 19, 2026Source: Drugs@FDA, ClinicalTrials.gov
NDAs and BLAs
5
3 still marketed
Novel approvals
0
Approvals since 2021
2
Originals and new uses
Phase 3 trials
7
Registered, any status
Trials by phase
All registered drug and biologic trials with this lead sponsor, any status. A public view of the pipeline.
Recent approvals
Originals and efficacy supplements, newest first.
- Onyda Xr approved May 24, 2024
- Dyanavel Xr 20 approved Nov 4, 2021
- Dyanavel Xr new use Feb 5, 2019
- Dyanavel Xr approved Oct 19, 2015
- Tuzistra Xr approved Apr 30, 2015
- Clonidine approved Dec 3, 2009
Drugs in development (1)
Investigational drugs, not yet FDA-approved, in this company's active or recent Phase 2 and 3 trials. Phase 3 first.
- CebranopadolTRN-228Phase 34 trials
Adneuris Therapeutics, Inc. · Pain, Acute Pain, Chronic Pain
Recruiting Phase 3 trials
Largest first.
No recruiting Phase 3 trials under this sponsor name.
Marketed drugs (3)
Newest FDA action first.
- Dyanavel Xr Amphetamine, Amphetamine Aspartate/Dextroamphetamine Sulfate · 2015
- Dyanavel Xr 20 Amphetamine, Amphetamine Aspartate/Dextroamphetamine Sulfate · 2021
- Onyda Xr Clonidine Hydrochloride · 2024
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.